Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Depreciation (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Accumulated Depreciation data on record, last reported at $169608.0 in Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $169608.0; the TTM value through Sep 2025 reached $169608.0, changed N/A, while the annual FY2024 figure was $123357.0, 32.93% up from the prior year.
  • Accumulated Depreciation reached $169608.0 in Q3 2025 per GANX's latest filing, up from $136778.0 in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $169608.0 in Q3 2025 and bottomed at $18466.0 in Q2 2021.
  • Average Accumulated Depreciation over 5 years is $87965.7, with a median of $92797.0 recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 119.98% in 2021, then soared 32.93% in 2024.
  • A 5-year view of Accumulated Depreciation shows it stood at $28389.0 in 2021, then skyrocketed by 87.85% to $53329.0 in 2022, then surged by 74.01% to $92797.0 in 2023, then skyrocketed by 32.93% to $123357.0 in 2024, then surged by 37.49% to $169608.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $169608.0 in Q3 2025, $136778.0 in Q1 2025, and $123357.0 in Q4 2024.